| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCGENETICS.111.961144 |
| P698 | PubMed publication ID | 22331829 |
| P50 | author | Paul Ridker | Q7153226 |
| Bryan J Barratt | Q47502862 | ||
| Daniel I Chasman | Q89708224 | ||
| Franco Giulianini | Q114293440 | ||
| P2093 | author name string | Jean MacFadyen | |
| Fredrik Nyberg | |||
| P2860 | cites work | Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) | Q33194199 |
| P433 | issue | 2 | |
| P921 | main subject | lipoprotein | Q28350 |
| LDL cholesterol | Q75298271 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 257-264 | |
| P577 | publication date | 2012-02-13 | |
| P1433 | published in | Circulation: Cardiovascular Genetics | Q15816430 |
| P1476 | title | Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial | |
| P478 | volume | 5 |
| Q48123127 | 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document |
| Q61804787 | A PheWAS study of a large observational epidemiological cohort of African Americans from the REGARDS study |
| Q47747535 | A common missense variant of LILRB5 is associated with statin intolerance and myalgia. |
| Q40817564 | A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering |
| Q51272834 | A genetic risk score is significantly associated with statin therapy response in the elderly population. |
| Q35511685 | A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians |
| Q92350874 | A phenome-wide association study (PheWAS) in the Population Architecture using Genomics and Epidemiology (PAGE) study reveals potential pleiotropy in African Americans |
| Q36054829 | Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia |
| Q57585223 | An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C |
| Q34157965 | Ancestry and other genetic associations with plasma PCSK9 response to simvastatin |
| Q34137872 | Anti-inflammatory therapies for cardiovascular disease |
| Q33994570 | Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. |
| Q36394580 | Association of MYLIP rs3757354 SNP and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations |
| Q42291683 | Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects |
| Q38208727 | Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. |
| Q38147841 | Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates |
| Q91693987 | Carotid Intima-Media Thickness: Novel Loci, Sex-Specific Effects, and Genetic Correlations With Obesity and Glucometabolic Traits in UK Biobank |
| Q57822685 | Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort |
| Q57316344 | Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events |
| Q37579733 | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care |
| Q89110431 | Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias |
| Q36199734 | Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures |
| Q51304354 | Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome. |
| Q33686542 | Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers |
| Q38071700 | Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications |
| Q36152978 | Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia. |
| Q46062183 | Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients |
| Q50082577 | Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. |
| Q90614437 | Ethnogeographic and inter-individual variability of human ABC transporters |
| Q38095872 | Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering |
| Q27026358 | Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer |
| Q38155218 | Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin |
| Q27026250 | Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis |
| Q91736525 | Genetic contribution to lipid target achievement with statin therapy: a prospective study |
| Q49931634 | Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. |
| Q34803027 | Genome-wide family-based linkage analysis of exome chip variants and cardiometabolic risk |
| Q36747275 | Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. |
| Q38176273 | How low an LDL-C should we go with statin therapy? |
| Q35557701 | IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population |
| Q38663481 | Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. |
| Q36730132 | Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study |
| Q88585720 | Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia |
| Q52431756 | Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective from the International Transporter Consortium. |
| Q45082643 | International Transporter Consortium commentary on clinically important transporter polymorphisms. |
| Q57285996 | KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment |
| Q38240747 | LDL cholesterol: controversies and future therapeutic directions |
| Q38129422 | Lipid-lowing pharmacogenomics in Chinese patients |
| Q38212170 | Liver X receptors in lipid metabolism: opportunities for drug discovery |
| Q57117258 | Liver X receptors in lipid signalling and membrane homeostasis |
| Q99610610 | Loci identified by a genome-wide association study of carotid artery stenosis in the eMERGE network |
| Q30276013 | Meta-analysis of genome-wide association studies of HDL cholesterol response to statins |
| Q30354462 | Meta-analysis of rare and common exome chip variants identifies S1PR4 and other loci influencing blood cell traits. |
| Q37279687 | Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? |
| Q24187425 | PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease |
| Q30234612 | PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease |
| Q36854531 | Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents |
| Q38756015 | Personalized medicine: Genetic risk prediction of drug response |
| Q46018199 | PharmGKB summary: very important pharmacogene information for ABCG2. |
| Q34680467 | Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins |
| Q34453666 | Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins |
| Q36974672 | Pharmacogenetics and cardiovascular disease--implications for personalized medicine |
| Q38094070 | Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. |
| Q38780996 | Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? |
| Q47357309 | Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments |
| Q38112823 | Pharmacogenomics of lipid-lowering therapies |
| Q38203774 | Pharmacogenomics, lipid disorders, and treatment options |
| Q34269364 | Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation |
| Q36387714 | Protective effects of sirtuins in cardiovascular diseases: from bench to bedside |
| Q28485187 | RHOA is a modulator of the cholesterol-lowering effects of statin |
| Q38438530 | RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol. |
| Q30244632 | Racial Differences in the Cholesterol-Lowering Effect of Statin |
| Q38644870 | Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments |
| Q30616911 | Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective |
| Q46544631 | Replication and fine-mapping of genetic predictors of lipid traits in African-Americans |
| Q33948919 | Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with [...] |
| Q92308785 | Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy |
| Q41160181 | Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner |
| Q37410969 | SLCO1B1 Polymorphisms and Statin-Induced Myopathy |
| Q36480609 | SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization |
| Q38670109 | Seventeen years of statin pharmacogenetics: a systematic review |
| Q55034030 | Statin Responses in Chinese Patients. |
| Q37227150 | Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. |
| Q38868416 | Statins and Their Effect on PCSK9-Impact and Clinical Relevance |
| Q47262709 | Systems Pharmacology Dissection of Cholesterol Regulation Reveals Determinants of Large Pharmacodynamic Variability between Cell Lines |
| Q36485405 | THE CHALLENGES IN USING ELECTRONIC HEALTH RECORDS FOR PHARMACOGENOMICS AND PRECISION MEDICINE RESEARCH |
| Q38170328 | Targeting inflammation: impact on atherothrombosis |
| Q51481319 | Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. |
| Q34667908 | The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice |
| Q34387744 | The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia |
| Q46376996 | The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy |
| Q38773033 | The genetics of drug efficacy: opportunities and challenges |
| Q92862394 | The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change |
| Q92151548 | The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article) |
| Q88868156 | Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease |
| Q38099195 | Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium |
| Q35645239 | Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials |
| Q58737227 | ZNF542P is a pseudogene associated with LDL response to simvastatin treatment |
Search more.